Sandra Lockmer

455 total citations
12 papers, 209 citations indexed

About

Sandra Lockmer is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Sandra Lockmer has authored 12 papers receiving a total of 209 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pathology and Forensic Medicine, 7 papers in Oncology and 6 papers in Genetics. Recurrent topics in Sandra Lockmer's work include Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Viral-associated cancers and disorders (5 papers). Sandra Lockmer is often cited by papers focused on Lymphoma Diagnosis and Treatment (11 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Viral-associated cancers and disorders (5 papers). Sandra Lockmer collaborates with scholars based in Sweden, Norway and United States. Sandra Lockmer's co-authors include Eva Kimby, Björn E. Wahlin, Hans Hagberg, Bjørn Østenstad, Stefan Peterson, Martin Erlanson, Oskar Hagberg, O. Lindén, Herman Nilsson‐Ehle and Weicheng Ren and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Sandra Lockmer

12 papers receiving 206 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandra Lockmer Sweden 5 190 154 80 46 29 12 209
H. Tilly France 4 204 1.1× 160 1.0× 76 0.9× 9 0.2× 54 1.9× 7 229
Jesse Shustik Canada 5 114 0.6× 78 0.5× 50 0.6× 8 0.2× 27 0.9× 11 142
Antonella Anastasia Italy 10 216 1.1× 161 1.0× 78 1.0× 8 0.2× 92 3.2× 21 284
Bipinkumar Amin United States 5 91 0.5× 121 0.8× 68 0.8× 7 0.2× 19 0.7× 5 182
Felicia Gomez United States 4 200 1.1× 137 0.9× 114 1.4× 10 0.2× 14 0.5× 8 250
Farheen Mir United Kingdom 6 109 0.6× 74 0.5× 25 0.3× 39 0.8× 23 0.8× 13 167
Joan E. Ramis-Zaldivar Spain 5 165 0.9× 111 0.7× 89 1.1× 3 0.1× 45 1.6× 6 183
Allison Barraclough Australia 8 106 0.6× 87 0.6× 30 0.4× 4 0.1× 35 1.2× 29 152
A. Lopez-Guillermo Spain 4 84 0.4× 63 0.4× 74 0.9× 12 0.3× 7 0.2× 5 130
David Šálek Czechia 8 130 0.7× 102 0.7× 44 0.6× 3 0.1× 20 0.7× 23 156

Countries citing papers authored by Sandra Lockmer

Since Specialization
Citations

This map shows the geographic impact of Sandra Lockmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Lockmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Lockmer more than expected).

Fields of papers citing papers by Sandra Lockmer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Lockmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Lockmer. The network helps show where Sandra Lockmer may publish in the future.

Co-authorship network of co-authors of Sandra Lockmer

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Lockmer. A scholar is included among the top collaborators of Sandra Lockmer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Lockmer. Sandra Lockmer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Uggla, Bertil, Camilla Virta, Merit Melin, et al.. (2025). Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia. Haematologica. 110(8). 1774–1785. 1 indexed citations
2.
Nahi, Hareth, Katarina Uttervall, Sandra Lockmer, et al.. (2023). Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma. Cancer Medicine. 12(22). 20736–20744. 2 indexed citations
3.
Leich, Ellen, Tobias S. Schmidt, Michael Altenbuchinger, et al.. (2023). Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy. Leukemia & lymphoma. 64(12). 1927–1937. 2 indexed citations
4.
Weibull, Caroline E., Tove Wästerlid, Björn E. Wahlin, et al.. (2023). Survival by First-line Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A National Population-based Study in Sweden. HemaSphere. 7(3). e838–e838. 5 indexed citations
5.
Kiserud, Cecilie E., et al.. (2022). Health-related quality of life and chronic fatigue in long-term survivors of indolent lymphoma – a comparison with normative data. Leukemia & lymphoma. 64(2). 349–355. 3 indexed citations
6.
Lockmer, Sandra, et al.. (2020). Absolute B cell counts in blood predict long-term response in follicular lymphoma patients treated with rituximab without chemotherapy. Annals of Hematology. 99(10). 2357–2366. 2 indexed citations
7.
Kimby, Eva, Sandra Lockmer, Harald Holte, et al.. (2020). The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy. British Journal of Haematology. 191(5). 738–747. 12 indexed citations
8.
Lockmer, Sandra, Weicheng Ren, Bjørn Østenstad, et al.. (2019). M7‐FLIPI is not prognostic in follicular lymphoma patients with first‐line rituximab chemo‐free therapy. British Journal of Haematology. 188(2). 259–267. 44 indexed citations
9.
Lockmer, Sandra, Weicheng Ren, Bjørn Østenstad, et al.. (2018). M7-FLIPI Not Valid in Follicular Lymphoma Patients with First-Line Rituximab Chemo-Free Therapy. Blood. 132(Supplement 1). 4154–4154. 2 indexed citations
10.
Lockmer, Sandra, Bjørn Østenstad, Hans Hagberg, et al.. (2018). Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up. Journal of Clinical Oncology. 36(33). 3315–3323. 40 indexed citations
11.
12.
Peterson, Stefan, Eva Kimby, Sandra Lockmer, et al.. (2014). Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study. Leukemia. 29(3). 668–676. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. Tilly Breakdown of academic impact, for papers by Jesse Shustik Breakdown of academic impact, for papers by Antonella Anastasia Breakdown of academic impact, for papers by Bipinkumar Amin Breakdown of academic impact, for papers by Felicia Gomez Breakdown of academic impact, for papers by Farheen Mir Breakdown of academic impact, for papers by Joan E. Ramis-Zaldivar Breakdown of academic impact, for papers by Allison Barraclough Breakdown of academic impact, for papers by A. Lopez-Guillermo Breakdown of academic impact, for papers by David Šálek
Rankless by CCL
2026